IBIO · trading date Oct 9, 2026 · previous close $0.91 · source: Alpaca (IEX feed, not consolidated full-market data).
Key Financials
Revenue
$100.0K
Net income
-$33.04M
Total assets
$99.11M
Total liabilities
$13.40M
Stockholders' equity
$85.71M
Cash & equivalents
$56.40M
Operating income
-$35.14M
Operating cash flow
-$23.22M
Capital expenditures
$578.0K
Fiscal year 2026, via 10-K filed 2026-08-28.
A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
-35,141.0%
Net margin
-33,044.0%
Free cash flow
-$23.80M
Free cash flow margin
-23,796.0%
Liabilities / assets
13.5%
Equity / assets
86.5%
CapEx / revenue
578.0%
Operating cash flow / net income
0.70×
Derived from the fiscal year 2026 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
New York, NY 10022-1737
600 MADISON AVENUE, SUITE 1601
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 16:04 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.